医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpinalCyte, LLC Receives New Australian Patent for Spinal Disc Tissue Engineering

2015年10月14日 PM11:17
このエントリーをはてなブックマークに追加


 

HOUSTON

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Australian Patent No. 2013257540, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent involves using an absorbable membrane scaffold to support the growth of new cells populating the nucleus. Other claims provide for a semi-permeable membrane which allows for diffusion of nutrients. The membrane will be used to transfer the intermittent hydrostatic pressure onto the differentiating chondrocyte cells.

“The new Australian Patent broadens our protection internationally and protects our unique technology in one of the fastest growing markets for biologic repair of tissue,” said Pete O’Heeron, Chief Executive Officer. “We are pleased the Australian Commissioner of Patents has recognized the uniqueness of our technology.” SpinalCyte’s patent portfolio includes 11 U.S. and foreign patents issued and directly owned by the company, along with 17 patents pending.

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a cartilage regeneration technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151014005351/en/

CONTACT

SpinalCyte, LLC
Pete O’Heeron, 281.461.6211
CEO
pete@spinalcyte.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆